South San Francisco oncology specialist CytomX raised a $20 million C round to advance its in-house pipeline of novel cancer treatments, with partner Pfizer pouring in the lion's share of the new cash.
After 2014's growth spurt, Pfizer's vaccines unit is not done expanding. The pharma giant has grabbed privately held Swiss company Redvax for an undisclosed sum, adding a preclinical human cytomegalovirus (CMV) vaccine candidate and a tech platform and IP related to a second, undisclosed vaccine program.
2014 was a busy year for Pfizer's vaccines unit, and it looks like the pharma giant's ready to keep the ball rolling as the new year kicks off. Just over a month after closing its buyout of Baxter's vaccines unit, it's acquired Switzerland's Redvax for an undisclosed sum.
Pfizer has added an acquisition pact to its latest string of deals. The pharma giant said today that it is buying out Redvax, a subsidiary of Switzerland's Redbiotec, in order to get its hands on a preclinical cytomegalovirus (CMV) vaccine candidate.
The world of gene therapy--in which single-dose treatments correct debilitating defects--enjoyed something of a renaissance in 2014. Strong clinical results from leaders in the once-maligned field spurred renewed optimism, helping a new generation of startups secure millions in venture financing to develop their next-generation approaches to the field.
In one interview published over the weekend, AstraZeneca CEO Pascal Soriot pooh-poohed the idea of Pfizer coming back with another takeover bid. In another, he gave a subtle warning about his company's stated goal of hitting $45 billion in sales within a decade.
Anyone who's watched a Viagra commercial knows that Pfizer isn't too embarrassed to talk about sex. Anyone who's run across Pfizer's "Get Old" campaign knows it doesn't shy away from aging, either. Now, the drug giant is going equal opportunity on the sex-and-aging talk, and "Desperate Housewives" actress Brenda Strong has the dialogue.
Pfizer's business development team is on a spending spree. Today the pharma giant said it is partnering with Miami-based Opko Health on a Phase III long acting growth hormone, paying $295 million upfront and promising up to $275 million more on regulatory milestones.
Pfizer is experimenting with a mobile app to enroll rare disease patients in a study. The trial is comparing the DNA of people with congenital analgesia to unaffected family members.
Everyone who's ever applied for a job fears that recruiters will glance at their resumes and toss them out. Apparently, Pfizer's Swedish operation feared the same thing--and it tossed out the whole process.